Ottawa, Canada- January 5th, 2023- Virica Biotech Inc. ("Virica"), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023. Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica’s commercial efforts to drive [...]

With the holidays upon us, it is time to reflect on what Virica Biotech has accomplished in 2022, thanks to the hard work of our employees and partners. Read the full letter here.

Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. Tune into this free webinar to learn [...]

Virica Biotech Awarded Best Abstract at ISCT 2022-San Francisco Our Data Scientist, Andrea Vervoot and VP of Scientific Operations, JonDavid De Jong represented Virica at International Society of Cell & Gene Therapy (ISCT) 2022 in San Francisco. Andrea Vervoot's abstract presentation on the Bioprocess Modelling of Upstream Viral Vector Production Enhancement won the Best Elevator [...]

For Immediate Release Virica Biotech Announces Collaboration with the Government of Canada to Make Gene Therapies More Accessible and Affordable for Canadians  Download full press release here. Ottawa, Canada – May 2, 2022 –Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, [...]

Virica's team have landed at BioProcess International in San Diego! Meet us at the Convention Center and let us talk about how we can increase your viral vector production output. We are located in the Exhibition Hall- Poster Board #29

OTTAWA ,Canada– January 24th, 2022 – Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's [...]

Virica is excited to be a part of Advanced Therapies Week, Jan 25th-Jan28th, 2022 at the Miami Convention Center.  We are a proud to be a Dynamk Capital portfolio company. Visit us in the Technology of Tomorrow Zone, Booth 11. We look forward to meeting you at Advance Therapies Week! [...]

Please take a moment to watch Virica's Year in Review. We couldn’t have achieved these milestones without you, so thank you.

We now have officially launched our Process Innovation Facility! Take a look at where we enhance the manufacturing of viral medicine.